Halozyme

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

Retrieved on: 
Tuesday, April 9, 2024
College, Neurology, Neoplasm, Brain, M.B.A, Utrecht University, Oncology, Neuro, Central nervous system, Novartis, CNS, GBM, Biostatistics, Committee, Biology, Breast, University, Neurosurgery, PSTV, Cancer, Plus, Science park, Doctor of Philosophy, Glioblastoma, Therapy, Texas A&M University, Drug development, Halozyme, Plus Therapeutics, Pharmaceutical industry

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.

Key Points: 
  • Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory.
  • In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
  • Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors.
  • Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research.

Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, February 8, 2024
Therapy, Halozyme, SAN

SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading.

Key Points: 
  • SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading.
  • Halozyme will host a conference call on Tuesday, February 20, 2024 at 1:30 p.m. PT/4:30 p.m.
  • ET to discuss the results.
  • The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871904 .

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
Wednesday, November 15, 2023
Rubius, IL-2, Mural, Cytokine, Research, General counsel, Alexion, Therapy, Head, Arbutus Biopharma, Jazz Pharmaceuticals, Patient, Doctor of Philosophy, Protein engineering, Bristol Myers Squibb, Pembrolizumab, IL-12, Alkermes (company), Halozyme, AbbVie, MBA, YM Biosciences, El Rubius, Nivolumab, Ipilimumab, ImClone Systems, Mirati Therapeutics, BMS, Financial toxicity, Mucosal melanoma, FRCP, The Celator, Cancer, PROC, GSK plc, Pharmaceutical industry, Vaccine, Management, Exelixis, Merck, Immunogen

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, November 13, 2023
Neurogranin, Plasma, CSF, PIN, Administration, Patient, Research, FDA, Caregiver, Pharmacology, Halozyme, ABOS, Cash balance plan, Clinical trial, R, Research and development, Biomarker, Pharmaceutical industry, Vaccine, Cryptocurrency, G&A, Acumen

ET

Key Points: 
  • ET
    CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2023 and provided a business update.
  • “We have also observed encouraging trends in CSF biomarker data from our Phase 1 study, further solidifying the pharmacology of ACU193.
  • In October 2023, the Company met with the FDA to discuss the next clinical trial in the development program for ACU193.
  • Acumen will host a conference call and live audio webcast today, Nov. 13, 2023, at 8:00 a.m.

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

Retrieved on: 
Thursday, November 16, 2023
Acetylcholine receptor, Food, European Commission, Immunoglobulin G, GMG, Patient, CHMP, Committee, Efgartigimod alfa, Pharmaceutical industry, Vaccine, Halozyme

SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received European Commission (EC) approval of VYVGART® SC (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE® for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The European approval of VYVGART SC provides the option for patient self-administration. The EC approval is applicable to all 27 European Union Member States plus Iceland, Norway and Liechtenstein.

Key Points: 
  • The European approval of VYVGART SC provides the option for patient self-administration.
  • The EC approval is applicable to all 27 European Union Member States plus Iceland, Norway and Liechtenstein.
  • VYVGART® SC was approved by the U.S. Food and Drug Administration in June 2023 and is marketed as VYVGART® Hytrulo.
  • ADAPT-SC established the efficacy of VYVGART® SC by demonstrating a reduction in anti-AChR antibody levels comparable to VYVGART® IV in adult gMG patients.

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Retrieved on: 
Monday, November 6, 2023
AD, Pharmacokinetics, ABOS, Patient, Pharmaceutical industry, Acumen, Halozyme

The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.

Key Points: 
  • The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.
  • ENHANZE® has been commercially validated in seven approved therapies, with global collaborations covering more than 60 therapeutic targets.
  • Under the terms of the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE®.
  • Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales-based milestones.

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

Retrieved on: 
Monday, November 6, 2023
Alzheimer's disease, AD, Food, Fast Track, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dementia, Disease, World Health Organization, Partnership, Therapy, Patient, Mab, SAN, Pharmaceutical industry, Acumen, Halozyme

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme's ENHANZE® drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target. Acumen intends to explore the potential use of ENHANZE® for ACU193, Acumen's clinical-stage monoclonal antibody (mAb) candidate to target Amyloid-β Oligomers (AβOs) for the treatment of early Alzheimer's disease (AD).

Key Points: 
  • Under the terms of the agreement, Acumen will make an upfront payment to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment.
  • Halozyme will also be entitled to single digit royalties on net sales of commercialized medicines with the ENHANZE® technology.
  • ACU193 has been granted Fast Track designation for the treatment of early Alzheimer's disease by the U.S. Food and Drug Administration.
  • This deal marks Halozyme's thirteenth global collaboration and license partner for the ENHANZE® technology.

Halozyme To Report Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Monday, October 30, 2023
Halozyme, Therapy, SAN, Pharmaceutical industry, Communications satellite

SAN DIEGO, Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.

Key Points: 
  • SAN DIEGO, Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, November 6, 2023, following the close of trading.
  • Halozyme will host a conference call on Monday, November 6, 2023 at 1:30 p.m. PT/4:30 p.m.
  • ET to discuss the results.
  • The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/attendee/504047695 .

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Retrieved on: 
Thursday, October 19, 2023
Bristol Myers Squibb, Third wave, BMS, Pharmacokinetics, ORR, Serum, Safety, Therapy, Patient, SAN, Pharmaceutical industry, Medical imaging, Nivolumab, Halozyme

SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with ENHANZE® in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. The study met its co-primary pharmacokinetics endpoints and key secondary endpoint.

Key Points: 
  • SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from the Phase 3 CheckMate-67T trial evaluating a subcutaneous (SC) formulation of Opdivo (nivolumab) with ENHANZE® in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.
  • The study met its co-primary pharmacokinetics endpoints and key secondary endpoint.
  • Subcutaneous nivolumab showed noninferiority of objective response rate (ORR) by Blinded Independent Central Review (BICR) vs. IV Opdivo, a key secondary endpoint.
  • BMS will share detailed results from the CheckMate-67T trial at an upcoming medical meeting and work with health authorities on next steps for SC nivolumab across multiple indications.

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Tuesday, September 19, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Central nervous system, Drug development, Therapy, Senior, Hologic, ACAD, Corporate communication, Wall Street, Minerva Surgical, Inc. v. Hologic, Inc., Torosyan v. Boehringer Ingelheim Pharmaceuticals, Inc., Saint Petersburg State University of Economics and Finance, Patient, Vital, Incorporated, Growth, Management, Economics, Halozyme, Boston College

(Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications.

Key Points: 
  • (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications.
  • Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee.
  • “Al brings to Acadia a strong track record of leading investor relations and corporate communications functions at numerous growth-oriented companies across the healthcare industry,” said Mark Schneyer, Executive Vice President, Chief Financial Officer.
  • Prior to Halozyme, Al oversaw investor relations and business development at Vital Therapies, Inc., and investor relations at Hologic, Inc. and Gen-probe Incorporated.